|
|||||
|
|
Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide |
|
| Authors: | Carlos Alatorre MBA PhD Laura Fernández Landó MD Maria Yu MS Katelyn Brown Pharm D Leslie Montejano MA CCRP Paul Juneau MS Reema Mody MBA PhD Ralph Swindle PhD |
| Affiliation: | 1. Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana;2. Lilly USA, LLC, Lilly Corporate Center, Indianapolis, Indiana;3. Eli Lilly Canada Inc., Toronto, Ontario, Canada;4. Truven Health Analytics, an IBM Company, Ann Arbor, Michigan |
| Abstract: | |
| Keywords: | adherence augmentation glucagon‐like peptide‐1 receptor agonists persistence real‐world evidence switching type 2 diabetes mellitus |